PAVmed develops medical devices, diagnostics and digital health tools, including the EsoGuard test for esophageal precancer screening. PAVM reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 27 | Ascendiant Capital | Target raised | Buy | |
| Jun 8 | Ascendiant Capital | Maintained | Buy |
Seasonality
How PAVM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
Whale Options Flow
90DNo whale options trades in PAVM in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PAVM is in one of them and how their past PAVM trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PAVM in an article yet. Here's the latest on the wider market.
About PAVmed
PAVmed is a New York based company that works in medical devices, diagnostics and digital health. Its main product is the EsoGuard test, a DNA test run on cells collected with the EsoCheck device, which is offered to doctors, health systems, employers and patients to screen people with chronic acid reflux for esophageal precancer. Its Veris Health unit provides digital tools for cancer patients during and after treatment. The company is also developing PortIO, an implantable vascular access device.
- Headquarters
- New York, NY